Genetic Technologies (ASX:GTG) Total Stockholders Equity: A$1.83 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Technologies Total Stockholders Equity?

Genetic Technologies ASX:GTG Total Stockholders Equity is A$1.83 Mil as of Jun. 2024.

Genetic Technologies's Total Stockholders Equity for the quarter that ended in Jun. 2024 was A$1.83 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Genetic Technologies's Book Value per Share for the quarter that ended in Jun. 2024 was A$0.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Genetic Technologies's Debt-to-Equity for the quarter that ended in Jun. 2024 was 0.48.

Genetic Technologies  (ASX:GTG) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Genetic Technologies's Book Value per Share for the quarter that ended in Jun. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1.83-0)/132.217
=0.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Genetic Technologies's Debt-to-Equity for the quarter that ended in Jun. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.852 + 0.023) / 1.83
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Total Stockholders Equity Related Terms

Genetic Technologies Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Total Stockholders Equity Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.99 21.53 16.43 11.16 1.83

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 4.81 0.00 1.83 0.00
What does a Total Stockholders Equity of A$1.83 Mil mean?
Genetic Technologies (ASX:GTG) has a Total Stockholders Equity of A$1.83 Mil as of Jun. 2024. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Genetic Technologies and its competitors.
Is Genetic Technologies' Total Stockholders Equity too high?
Genetic Technologies' current Total Stockholders Equity is A$1.83 Mil.
How does Genetic Technologies' Total Stockholders Equity compare to LDDD and NOTV?
Genetic Technologies' Total Stockholders Equity of A$1.83 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Diagnostics & Research company?
A good Total Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Genetic Technologies and its competitors. Genetic Technologies's current Total Stockholders Equity is A$1.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current Total Stockholders Equity of A$1.83 Mil. The current Total Stockholders Equity is A$1.83 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current Total Stockholders Equity is A$1.83 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.